Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Sch 1 Update - ISIS Resources

15 Sep 2006 11:23

AIM15 September 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: Verona Pharma plc (previously Isis Resources plc) COMPANY ADDRESS: Adderbury Hill Barn, Milton Road, Adderbury, Oxon COMPANY POSTCODE: OX17 3HN COUNTRY OF INCORPORATION: United Kingdom COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: The company is involved in drug discovery focused on the discovery and development of new therapeutic drugs for thetreatment of allergic rhinitis (hay fever) and other chronic respiratory and inflammatory diseases. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 144,275,000 Ordinary Shares of £0.001 each CAPITAL TO BE RAISED ON ADMISSION: £2.043 million FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Professor Clive Peter Page, Non-Executive Chairman Professor Michael John Alfred Walker, Chief Executive Officer Claire Louise Poll, Executive Director Professor Trevor Mervyn Jones, Non-Executive Director Herbert Stuart Bottomley, Non-Executive Director PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Prior to Admission %Craig Burton* 19.9Pershing Keen Nominees Ltd** 18.5Williams de Broe 7.0Stuart Bottomley*** 7.0Josef El Raghy 6.0Fitel Nominees Ltd a/c CO57658 5.6Jamie Boyton 4.8William Fairweather 4.6Fitel Nominees Ltd a/c CO58142 4.2Mark Freeman 4.0Tolle Investments Pty Ltd 4.0 * Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A/C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited After admission %Fidelity Euro Smaller Companies Fund 9.70Craig Burton* 8.66Pershing Keen Nominees Ltd** 6.42Williams de Broe 5.80Stuart Bottomley*** 4.16Clive Page 3.92Michael Walker 3.91David Saint 3.91Millenium Capital Partners 3.19* Mr. Burton's interests are held through the CI Burton Family Trust A/C and CI Burton Super Fund A /C ** Pershing Keen Nominees Ltd holds an additional 3,000,000 ordinary shares on behalf o f Josef El Raghy, a director of the Company *** Mr. Bottomley's interests are held through The Bank of New York (Nominees) Limited NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: None ANTICIPATED ACCOUNTING REFERENCE DATE: 31 December EXPECTED ADMISSION DATE: 19 September 2006 NAME AND ADDRESS OF NOMINATED ADVISER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ NAME AND ADDRESS OF BROKER: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: Hanson Westhouse LLP 12th Floor One Angel Court London EC2R 7HJ DATE OF NOTIFICATION:15 September 2006UPDATE Update This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Oct 20186:00 amGNWVerona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
26th Oct 201810:12 amGNWData from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
27th Sep 20187:00 amGNWVerona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018
13th Sep 20181:00 pmGNWVerona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress
7th Aug 20187:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
2nd Mar 20184:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20184:35 pmRNSPrice Monitoring Extension
30th May 20177:00 amRNSHolding(s) in Company
30th May 20177:00 amRNSHolding(s) in Company
25th May 20175:27 pmRNSHolding(s) in Company
23rd May 20178:44 amRNSHolding(s) in Company
16th May 20177:44 amRNSPartial Exercise of Over-Allotment Option
9th May 20173:36 pmRNSHolding(s) in Company
8th May 20175:33 pmRNSHolding(s) in Company
5th May 20173:32 pmRNSHolding(s) in Company
5th May 201712:15 pmRNSHolding(s) in Company
5th May 201711:36 amRNSHolding(s) in Company
3rd May 20176:02 pmRNSHolding(s) in Company
3rd May 20172:49 pmRNSBlock Listing Application and Review
3rd May 201712:34 pmRNSGrant of Options and RSUs and PDMR Dealings
2nd May 20176:10 pmRNSClosing of Global Offering and Total Voting Rights
2nd May 20177:00 amRNSDirector/PDMR Shareholding
28th Apr 20175:40 pmRNSDirector/PDMR Shareholding
27th Apr 20177:00 amRNSPricing of Offering and Approval to List on NASDAQ
19th Apr 20177:00 amRNSGlobal Offering and Application to List on NASDAQ
18th Apr 20177:00 amRNSFDA Authorisation to Proceed RPL554 Investigation
12th Apr 20171:19 pmRNSResult of AGM
4th Apr 20177:14 amRNSFiles Statement for Proposed Global Offering
4th Apr 20177:00 amRNSFiles Statement for Proposed Global Offering
4th Apr 20177:00 amRNS1st Patient Dosed in Ph2a Trial for RPL554 in CF
3rd Apr 20177:00 amRNSBoard Change
31st Mar 20177:00 amRNSCOPD Collaboration and New Commercial Director
22nd Mar 20177:00 amRNSServices Agreement with QuintilesIMS
20th Mar 20171:55 pmRNSPosting of Annual report & Notice of AGM
2nd Mar 20179:36 amRNSPDMR Dealing
27th Feb 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSNotice of Results
22nd Feb 20177:00 amRNSFirst COPD patient dosed with RPL554
13th Feb 20177:00 amRNSTotal Voting Rights & Block Listing Interim Review
8th Feb 20171:31 pmRNSResult of General Meeting and Share Consolidation
18th Jan 20177:00 amRNSPublication of Circular
11th Jan 20177:00 amRNSHolding(s) in Company
4th Jan 201710:16 amRNSHolding(s) in Company
29th Dec 20164:40 pmPRNIssue of Equity
23rd Nov 20169:17 amPRNRegistered Initial Public Offering in the US
28th Oct 20167:00 amRNSExercise of options
26th Oct 20167:00 amPRNSecond Venture and Innovation Award from the CF Trust
19th Oct 20161:00 pmPRNNotice of Cancellation of Trading on Xetra
28th Sep 201610:49 amRNSExercise of options
26th Sep 20167:00 amPRNAppointment of CFO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.